Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Esperion Therapeutics reported Q1 2026 revenue of $80.1 million, up from $65.0 million a year earlier, and a narrower net loss of $25.2 million versus $40.5 million. Product sales were $43.4 million and collaboration revenue $36.7 million, driven mainly by partners in Europe and Japan.
Cash and cash equivalents were $156.2 million, alongside substantial obligations including a $291.2 million royalty sale liability and $250 million of term and convertible debt. The company agreed to acquire Corstasis for $75 million plus up to $180 million in milestones, adding Enbumyst to its cardiovascular portfolio.
Separately, Esperion entered into a definitive merger agreement under which Essence Parent Inc. will acquire the company. Holders of common stock will receive $3.16 in cash per share plus one contingent value right tied to up to $100 million of potential milestone-based cash payments, subject to stockholder approval and customary conditions.
Esperion Therapeutics agreed to be acquired by Essence Parent Inc., an affiliate of ARCHIMED. Under the merger agreement, shareholders will receive $3.16 in cash per share plus one contingent value right (CVR) per share, which can pay up to $100 million in cash in total if specified milestones are met.
The deal values Esperion’s equity at up to approximately $1.1 billion on a fully diluted basis and the cash price reflects a 58% premium to the April 30, 2026 closing share price. The transaction, unanimously approved by Esperion’s board, is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals and other customary conditions. Termination fees are set at $68,309,078 for Parent and $34,154,539 for Esperion in specified circumstances.
Esperion Therapeutics ownership disclosure: institutional investor Wasatch Advisors reports beneficial ownership of 15,768,897 shares of Common Stock, representing 6.1% of the class. The filing shows sole voting power of 12,377,523 shares and sole dispositive power of 15,768,897. The filing is signed by Mike Yeates, CEO, dated 04/22/2026.
Esperion Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on May 28, 2026. Stockholders will elect two Class I directors, approve on a non-binding basis the compensation of named executive officers, and ratify Ernst & Young LLP as auditor for 2026.
The company also seeks approval of an amendment to its 2022 Stock Option and Incentive Plan to increase the shares of common stock authorized for issuance under the plan by 7,000,000 shares, raising the plan’s share limit from 23,150,000 to 30,150,000. Esperion had 257,404,876 common shares outstanding as of March 31, 2026, each entitled to one vote.
The board states that equity awards are a key component of compensation, used to attract and retain employees and align their interests with stockholders. All directors (except the CEO) are deemed independent under Nasdaq rules, and the board maintains audit, compensation, nominating and governance, commercial, and compliance committees to oversee financial reporting, pay, board composition, commercial strategy, and regulatory compliance.
Esperion Therapeutics completed the acquisition of Corstasis Therapeutics, making Corstasis a wholly owned subsidiary and adding Enbumyst, an FDA‑approved bumetanide nasal spray for edema in cardiovascular, hepatic and renal disease. The company paid $75,000,000 in upfront cash, with Corstasis equityholders eligible for up to $180,000,000 in milestone payments plus future royalty and licensing‑revenue‑based payments.
To help fund the deal, Esperion amended its credit agreement to add $25,000,000 of new term loans and entered a Royalty Purchase Agreement, selling a portion of Otsuka‑related Bempedoic Acid royalties and milestones to Athyrium for $50,000,000. Athyrium will receive 100% of these specified receivables until it has collected $100,000,000, after which all such payments revert to Esperion.
The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting zero shares of Common Stock of Esperion Therapeutics Inc. as beneficially owned. The filing states 0 shares (0%) and lists zero voting and dispositive powers.
The filing includes a disclosure that certain Vanguard subsidiaries were disaggregated after an internal realignment effective January 12, 2026, and that those subsidiaries will report separately under SEC Release No. 34-39538.
Esperion Therapeutics, Inc. Chief Legal Officer Benjamin Looker reported an open-market sale of 5,708 shares of common stock. The shares were sold at an average price of $2.703 per share to satisfy tax obligations on vested restricted stock units. After this transaction, he directly holds 679,348 shares, indicating that the sale represents a small portion of his overall position.
Esperion Therapeutics’ President and CEO Sheldon L. Koenig reported an open-market sale of 25,578 shares of common stock at $2.719 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from vested restricted stock units.
After this transaction, Koenig directly holds 2,172,699 shares of Esperion Therapeutics common stock. This filing reflects a tax-related disposition rather than a discretionary reduction of his overall shareholding.
Esperion Therapeutics Chief Financial Officer Benjamin Halladay reported an open-market sale of 6,424 shares of common stock at $2.705 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units. After this tax-related sale, he directly holds 713,602 shares.